Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Blood|September 16, 2011
Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphomaBoris Böll, Henning Bredenfeld, Helen Görgen, et al.
Anti-Cancer Drugs|September 23, 2009
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'Stefan Boeck, Ursula Vehling-Kaiser, Dirk Waldschmidt, et al.
BMC Cancer|December 31, 2018
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer groupThomas J Ettrich, Andreas W Berger, Lukas Perkhofer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 2019
Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcomaJoerg T Hartmann, Hans-G Kopp, Viktor Gruenwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2019
FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)Dominik P Modest, Uwe M Martens, Jorge Riera-Knorrenschild, et al.
Theranostics|March 15, 2019
A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic CancerAndreas W Berger, Daniel Schwerdel, Anke Reinacher-Schick, et al.
BMC Cancer|August 29, 2014
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104Steffen Ormanns, Jens T Siveke, Volker Heinemann, et al.
Cancers|February 15, 2022
Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb EfficacyAnnabel H S Alig, Volker Heinemann, Michael Geissler, et al.
Acta Oncologica (Stockholm, Sweden)|May 1, 2015
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104Stephan Kruger, Stefan Boeck, Volker Heinemann, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2018
PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO studyArndt Vogel, Stefan Kasper, Michael Bitzer, et al.
Pageof 6